ASCPRO Recommendations for the Assessment of Fatigue as an Outcome in Clinical Trials
Open Access
- 30 June 2010
- journal article
- guideline
- Published by Elsevier BV in Journal of Pain and Symptom Management
- Vol. 39 (6), 1086-1099
- https://doi.org/10.1016/j.jpainsymman.2010.02.006
Abstract
No abstract availableKeywords
Funding Information
- Alpharma; Amgen Inc.; Celgene Corporation; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck & Co., Inc.; Pfizer Inc.; and Purdue Pharma LP.
This publication has 63 references indexed in Scilit:
- The accuracy of pain and fatigue items across different reporting periodsPain, 2008
- Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritisJournal of Clinical Epidemiology, 2008
- A New Way of Thinking About Fatigue: A ReconceptualizationOncology Nursing Forum, 2007
- Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening toolSupportive Care in Cancer, 2004
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- Fatigue in Patients With CancerOncology Nursing Forum, 2002
- Fatigue associated with cancer and its treatmentSupportive Care in Cancer, 2001
- Development and Validation of the Cancer Fatigue ScaleJournal of Pain and Symptom Management, 2000
- The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigueJournal of Psychosomatic Research, 1995
- Measurement of health statusControlled Clinical Trials, 1989